CN1234407C - 一种治疗慢性前列腺炎的药物及其制备方法 - Google Patents
一种治疗慢性前列腺炎的药物及其制备方法 Download PDFInfo
- Publication number
- CN1234407C CN1234407C CNB2004100107518A CN200410010751A CN1234407C CN 1234407 C CN1234407 C CN 1234407C CN B2004100107518 A CNB2004100107518 A CN B2004100107518A CN 200410010751 A CN200410010751 A CN 200410010751A CN 1234407 C CN1234407 C CN 1234407C
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- hours
- rhizoma
- qianliekang
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 52
- 201000007094 prostatitis Diseases 0.000 title claims abstract description 20
- 208000013507 chronic prostatitis Diseases 0.000 title claims abstract description 13
- 229940079593 drug Drugs 0.000 title claims description 21
- 238000000034 method Methods 0.000 title abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 32
- 239000000284 extract Substances 0.000 claims abstract description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000001035 drying Methods 0.000 claims abstract description 8
- 238000010992 reflux Methods 0.000 claims abstract description 8
- 238000002156 mixing Methods 0.000 claims abstract description 7
- 239000000706 filtrate Substances 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 13
- 239000009636 Huang Qi Substances 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 11
- 238000005303 weighing Methods 0.000 claims description 9
- 239000007788 liquid Substances 0.000 claims description 8
- -1 filtered Substances 0.000 claims description 7
- 238000004064 recycling Methods 0.000 claims description 7
- 235000019640 taste Nutrition 0.000 claims description 5
- 238000012856 packing Methods 0.000 claims description 4
- 241000545442 Radix Species 0.000 claims description 2
- 230000001737 promoting effect Effects 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 18
- 230000017531 blood circulation Effects 0.000 abstract description 12
- 208000004880 Polyuria Diseases 0.000 abstract description 11
- 230000035619 diuresis Effects 0.000 abstract description 11
- 230000006870 function Effects 0.000 abstract description 6
- 239000000463 material Substances 0.000 abstract description 4
- 230000002708 enhancing effect Effects 0.000 abstract description 2
- 208000024891 symptom Diseases 0.000 abstract description 2
- 241000893536 Epimedium Species 0.000 abstract 3
- 235000018905 epimedium Nutrition 0.000 abstract 3
- 244000241838 Lycium barbarum Species 0.000 abstract 2
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 2
- 235000015468 Lycium chinense Nutrition 0.000 abstract 2
- 244000153955 Reynoutria sachalinensis Species 0.000 abstract 2
- 235000003202 Reynoutria sachalinensis Nutrition 0.000 abstract 2
- 235000003205 Smilax rotundifolia Nutrition 0.000 abstract 2
- 240000009022 Smilax rotundifolia Species 0.000 abstract 2
- 241000270666 Testudines Species 0.000 abstract 2
- 229940107666 astragalus root Drugs 0.000 abstract 2
- 235000013399 edible fruits Nutrition 0.000 abstract 2
- 238000001914 filtration Methods 0.000 abstract 2
- 230000003213 activating effect Effects 0.000 abstract 1
- 238000010298 pulverizing process Methods 0.000 abstract 1
- 238000011084 recovery Methods 0.000 abstract 1
- 229940126680 traditional chinese medicines Drugs 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 31
- 239000008280 blood Substances 0.000 description 31
- 241001465754 Metazoa Species 0.000 description 23
- 238000012360 testing method Methods 0.000 description 15
- 241000700159 Rattus Species 0.000 description 14
- 239000002775 capsule Substances 0.000 description 13
- 230000037396 body weight Effects 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 11
- 230000000242 pagocytic effect Effects 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 230000008961 swelling Effects 0.000 description 8
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 7
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 7
- 229960001138 acetylsalicylic acid Drugs 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 206010018691 Granuloma Diseases 0.000 description 6
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 206010000077 Abdominal mass Diseases 0.000 description 5
- 235000009161 Espostoa lanata Nutrition 0.000 description 5
- 240000001624 Espostoa lanata Species 0.000 description 5
- 206010063560 Excessive granulation tissue Diseases 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 210000001126 granulation tissue Anatomy 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 230000003908 liver function Effects 0.000 description 5
- 231100001252 long-term toxicity Toxicity 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 238000005728 strengthening Methods 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 235000010418 carrageenan Nutrition 0.000 description 4
- 229920001525 carrageenan Polymers 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000005911 diet Nutrition 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 206010020718 hyperplasia Diseases 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003907 kidney function Effects 0.000 description 4
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010067482 No adverse event Diseases 0.000 description 3
- 206010030113 Oedema Diseases 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000004856 capillary permeability Effects 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 229940109239 creatinine Drugs 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- 231100000614 poison Toxicity 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 208000008930 Low Back Pain Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229940126678 chinese medicines Drugs 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000031648 Body Weight Changes Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 208000034657 Convalescence Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 241000233855 Orchidaceae Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000032023 Signs and Symptoms Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 210000003484 anatomy Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 230000004579 body weight change Effects 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 235000021256 carbohydrate metabolism Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000037976 chronic inflammation Diseases 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000037308 hair color Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000004377 microelectronic Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000008517 radix Trichosanthis Substances 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Abstract
Description
组别 | 剂量 | 例数 | 光密度(OD)值 |
对照阿司匹林前列康舒前列康舒 | 0.5g/kg4.0g/kg2.0g/kg | 10101010 | 0.041±0.140.027±0.011*0.025±0.012*0.026±0.013* |
分组 | 剂量 | 动物数(只) | 致炎后 | 肿胀百分率 | 肿胀抑制百分率 |
空白对照阿司匹林前列康舒前列康舒 | 0.1g/kg2.0g/kg1.0g/kg | 10101010 | 0.5h1h2h4h6h0.5h1h2h4h6h0.5h1h2h4h6h0.5h1h2h4h6h | 14.2±4.514.4±3.116.5±4.617.6±5.214.7±4.18.8±3.2**9.4±3.8**11.2±3.2**11.9±3.1**10.4±3.8*10.1±2.6*10.7±2.8*11.5±3.1*11.7±3.2**10.8±3.4*10.3±2.7*10.2±2.4**11.1±2.6**12.0±3.4*11.2±2.2* | 38.0234.7232.1232.3829.2528.8734.5730.3033.5226.5327.4629.1632.7231.3123.80 |
组别 | 剂量 | 例数 | 棉球肉芽肿重量(mg/100g) |
空白对照阿斯匹林前列康舒前列康舒 | 0.1/kg2.0g/kg1.0g/kg | 10101010 | 388.4±86.2267.3±48.5**292.8±46.2**311.5±48.6* |
组别 | 剂量 | 例数 | 吞噬指数K | 吞噬活性α |
空白对照前列康舒前列康舒 | 4.0g/kg2.0g/kg | 101010 | 0.031±0.0110.059±0.024**0.051±0.017** | 5.15±0.886.87±1.69*6.49±1.74* |
组别 | 例数 | 0w | 1w | 2w | 3w | 4w |
对照组高剂量组低剂量组 | 202020 | 94.7±8.394.3±9.195.8±8.4 | 116.6±10.1116.7±10.3100.6±12.7 | 151.0±16.1137.1±17.3136.3±14.5 | 163.1±24.1158.8±18.6149.1±22.7 | 163.1±24.178.9±19.165.8±24 |
检测项目 | 对照组 | 高剂量组 | 低剂量组 |
RBC(1012/l)HCT(ml/100ml)Hb(g/100ml)Pit(109/l)WBC(109/l)Sg(%)Ly(%) | 5.08±0.4523.3±1.9613.3±0.66395.7±27.95.89±2.1520.5±6.8679.5±6.86 | 5.07±0.3524.2±1.6413.4±0.84380.9±33.95.83±2.3913.5±3.4286.5±3.42 | 5.83±0.6821.6±2.7014.0±1.45385.7±31.36.07±1.7919.3±5.1880.6±5.18 |
组别 | 例数 | AST(u/l) | ALT(u/l) | ALP(u/l) |
对照组高剂量低剂量 | 202020 | 168±33.80165±36.23191±56.03 | 66.2±11.7764.8±14.9768.8±13.88 | 156.14±49.16163.07±50.48172.28±68.59 |
组别 | 例数 | TP(g/l) | ALB(g/l) | T-BIL(umol/l) |
对照组高剂量低剂量 | 202020 | 61.1±3.562.3±3.962.6±4.3 | 31.7±1.730.5±2.431.4±2.9 | 3.64±0.725.36±1.675.50±1.29 |
组别 | 例数 | BUN(mmol/l) | CRE(umol/l) |
对照组高剂量低剂量 | 202020 | 4.34±0.766.15±1.884.72±0.78 | 53.9±5.0051.7±6.4550.5±6.92 |
组别 | 例数 | T-CHO(mmol/l) | GLU(umol/l) |
对照组高剂量低剂量 | 202020 | 1.66±0.181.87±0.291.64±0.22 | 4.64±0.413.98±0.643.74±0.68 |
组别 | 例数 | 心 | 肝 | 脾 | 肺 | 肾 |
对照组高剂量低剂量 | 202020 | 0.31±0.040.35±0.060.34±0.07 | 4.61±0.704.61±1.024.07±0.79 | 0.56±0.140.69±0.400.62±0.28 | 0.87±0.240.99±0.180.92±0.24 | 0.360.060.39±0.070.38±0.09 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100107518A CN1234407C (zh) | 2004-03-26 | 2004-03-26 | 一种治疗慢性前列腺炎的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100107518A CN1234407C (zh) | 2004-03-26 | 2004-03-26 | 一种治疗慢性前列腺炎的药物及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1562114A CN1562114A (zh) | 2005-01-12 |
CN1234407C true CN1234407C (zh) | 2006-01-04 |
Family
ID=34477883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100107518A Expired - Fee Related CN1234407C (zh) | 2004-03-26 | 2004-03-26 | 一种治疗慢性前列腺炎的药物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1234407C (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1733197B (zh) * | 2005-08-24 | 2010-06-09 | 王少金 | 一种治疗慢性前列腺炎的药物及其制备方法 |
CN101559154B (zh) * | 2009-06-03 | 2011-10-12 | 刘晓峰 | 一种治疗慢性前列腺炎的药物及其制备方法 |
CN101721528B (zh) * | 2009-12-30 | 2011-09-07 | 长春中医药大学 | 一种治疗慢性前列腺炎的药物组合物 |
CN103405717A (zh) * | 2013-08-10 | 2013-11-27 | 谢承宏 | 前列腺炎的中药 |
CN112410158A (zh) * | 2020-12-22 | 2021-02-26 | 和田昆玉中科生物科技有限公司 | 具有改善慢性前列腺疾病的牡丹保健酒及制备方法 |
-
2004
- 2004-03-26 CN CNB2004100107518A patent/CN1234407C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1562114A (zh) | 2005-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1305513C (zh) | 一种广谱治疗癌症的中药制剂及其制备方法 | |
CN1618446A (zh) | 一种治疗糖尿病的药物及其制备方法 | |
CN102988675B (zh) | 一种治疗慢性前列腺炎的中药组合物及其制备方法 | |
CN108853433A (zh) | 一种治疗糖尿病肾病的中药及其制备方法 | |
CN1234407C (zh) | 一种治疗慢性前列腺炎的药物及其制备方法 | |
CN1117582C (zh) | 治疗类风湿关节炎的药物及其制备方法 | |
CN1197614C (zh) | 治疗前列腺疾病的中药胶囊 | |
CN1232279C (zh) | 一种降血脂的中药 | |
CN101658656B (zh) | 治疗胆石病的药物 | |
CN1264540C (zh) | 治疗急性黄疸肝炎的中药及其制备方法 | |
CN1628771A (zh) | 治疗妇科疾病的洗剂及其制备方法 | |
CN1772257A (zh) | 三七脂肝制剂及其制备方法 | |
CN1319555C (zh) | 一种治疗前列腺增生症的药物及制备方法 | |
CN1251751C (zh) | 一种治疗慢性肝病及抗肝纤维化的中药及其制备工艺 | |
CN1253196C (zh) | 一种治疗结肠炎的药物 | |
CN1057399A (zh) | 一种中药原子化痞散的制作方法 | |
CN100534486C (zh) | 一种治疗糖尿病肾病蛋白尿的中药制剂 | |
CN1269501C (zh) | 一种治疗慢性结肠炎的药物及制备方法 | |
CN100455317C (zh) | 治疗2型糖尿病的药物 | |
CN1733197B (zh) | 一种治疗慢性前列腺炎的药物及其制备方法 | |
CN1285367C (zh) | 一种治疗糖尿病的药物制剂及其制备方法 | |
CN104083548A (zh) | 一种治疗卵巢囊肿的中药组合物及其制备方法 | |
CN1471954A (zh) | 一种中药戒毒药物 | |
CN107737259A (zh) | 一种提高男性性功能的中药组方 | |
CN1840049A (zh) | 一种治疗糖尿病肾病的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Jilin yinnuoke Pharmaceutical Co.,Ltd. Assignor: Liu Xiaofeng Contract fulfillment period: 2009.9.2 to 2019.9.1 Contract record no.: 2009220000078 Denomination of invention: Medicine for treating chronic prostatitis and its preparing method Granted publication date: 20060104 License type: Exclusive license Record date: 20091027 |
|
LIC | Patent licence contract for exploitation submitted for record |
Free format text: EXCLUSIVE LICENSE; TIME LIMIT OF IMPLEMENTING CONTACT: 2009.9.2 TO 2019.9.1; CHANGE OF CONTRACT Name of requester: JILIN PROVINCE YINNUOKE PHARMACY CO., LTD. Effective date: 20091027 |
|
EM01 | Change of recordation of patent licensing contract |
Change date: 20160413 Contract record no.: 2009220000078 Assignee after: Zhenlai Bao Kang Pharmaceutical Co. Assignee before: Jilin yinnuoke Pharmaceutical Co.,Ltd. |
|
LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160601 Address after: 137000, No. 999, happy East Road, Zhenlai Economic Development Zone, Baicheng, Jilin Patentee after: Zhenlai Bao Kang Pharmaceutical Co. Address before: 130031 No. 23, conference Avenue, Changchun economic and Technological Development Zone, Jilin, China Patentee before: Liu Xiaofeng |
|
CP01 | Change in the name or title of a patent holder |
Address after: 137000, No. 999, happy East Road, Zhenlai Economic Development Zone, Baicheng, Jilin Patentee after: Jilin yinnuoke pharmaceutical Limited by Share Ltd. Address before: 137000, No. 999, happy East Road, Zhenlai Economic Development Zone, Baicheng, Jilin Patentee before: Zhenlai Bao Kang Pharmaceutical Co. |
|
CP01 | Change in the name or title of a patent holder | ||
CP03 | Change of name, title or address |
Address after: 137000, No. 999, happy East Road, Zhenlai Economic Development Zone, Jilin, Baicheng Patentee after: Jilin yinnuoke Pharmaceutical Co.,Ltd. Address before: 137000, No. 999, happy East Road, Zhenlai Economic Development Zone, Baicheng, Jilin Patentee before: Jilin yinnuoke pharmaceutical Limited by Share Ltd. |
|
CP03 | Change of name, title or address | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20060104 |
|
CF01 | Termination of patent right due to non-payment of annual fee |